Brain Metastasis-Pipeline Review, H1 2015

Brain Metastasis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6593IDB
  • |
  • Pages: 174
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Brain Metastasis-Pipeline Review, H1 2015


Global Markets Direct's, 'Brain Metastasis-Pipeline Review, H1 2015', provides an overview of the Brain Metastasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Metastasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Brain Metastasis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Brain Metastasis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Brain Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Brain Metastasis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Brain Metastasis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Brain Metastasis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Brain Metastasis Overview 10

Therapeutics Development 11

Pipeline Products for Brain Metastasis-Overview 11

Pipeline Products for Brain Metastasis-Comparative Analysis 12

Brain Metastasis-Therapeutics under Development by Companies 13

Brain Metastasis-Therapeutics under Investigation by Universities/Institutes 15

Brain Metastasis-Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Brain Metastasis-Products under Development by Companies 18

Brain Metastasis-Products under Investigation by Universities/Institutes 20

Brain Metastasis-Companies Involved in Therapeutics Development 21

AbbVie Inc. 21

AngioChem Inc. 22

BBB Therapeutics B.V. 23

biOasis Technologies Inc. 24

Bristol-Myers Squibb Company 25

Diffusion Pharmaceuticals LLC 26

e-Therapeutics plc 27

Exelixis, Inc. 28

GlaxoSmithKline plc 29

Hutchison MediPharma Limited 30

Komipharm International Co., Ltd. 31

Nanobiotix 32

Nektar Therapeutics 33

Nerviano Medical Sciences S.r.l. 34

Novartis AG 35

Pfizer Inc. 36

Philogen S.p.A. 37

Phosplatin Therapeutics LLC 38

Puma Biotechnology, Inc. 39

Radius Health, Inc. 40

Sanofi 41

Spectrum Pharmaceuticals, Inc. 42

Tocagen Inc. 43

Brain Metastasis-Therapeutics Assessment 44

Assessment by Monotherapy Products 44

Assessment by Combination Products 45

Assessment by Target 46

Assessment by Mechanism of Action 49

Assessment by Route of Administration 51

Assessment by Molecule Type 53

Drug Profiles 55

(dabrafenib mesylate + trametinib dimethyl sulfoxide)-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

2B3-101-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

ANG-1005-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

ANG-4043-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

BT-2111-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

cabazitaxel-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

cabozantinib s-malate-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

dabrafenib mesylate-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

dacomitinib-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

Drug for Brain Metastasis-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

etirinotecan pegol-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

ETS-2101-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Gene Therapy to Activate p53 for Oncology-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

HMPL-813-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

ipilimumab-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

KML-001-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

lapatinib ditosylate-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

lucanthone hydrochloride-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

NBTX-IV-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

neratinib-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

nimotuzumab-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

NMSE-973-Drug Profile 101

Product Description 101

Mechanism of Action 101

R&D Progress 101

PB-357-Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

PT-112-Drug Profile 103

Product Description 103

Mechanism of Action 103

R&D Progress 103

RAD-1901-Drug Profile 104

Product Description 104

Mechanism of Action 104

R&D Progress 104

radretumab-Drug Profile 106

Product Description 106

Mechanism of Action 106

R&D Progress 106

RRX-001-Drug Profile 108

Product Description 108

Mechanism of Action 108

R&D Progress 108

transcrocetinate sodium-Drug Profile 109

Product Description 109

Mechanism of Action 109

R&D Progress 109

veliparib-Drug Profile 110

Product Description 110

Mechanism of Action 110

R&D Progress 110

vocimagene amiretrorepvec + flucytosine ER-Drug Profile 113

Product Description 113

Mechanism of Action 113

R&D Progress 113

Brain Metastasis-Recent Pipeline Updates 115

Brain Metastasis-Dormant Projects 163

Brain Metastasis-Discontinued Products 164

Brain Metastasis-Product Development Milestones 165

Featured News & Press Releases 165

Aug 28, 2014: Radius Health Reports Proof of Mechanism for RAD1901 and Presentation at 4th Annual Brain Metastases Research and Emerging Therapy Conference in September 165

Nov 12, 2013: Study Demonstrates biOasis Technologies' Conjugate of Metastatic Cancer Drug, Herceptin, Penetrates Blood-Tumor Barrier 10 Times Greater Than Herceptin Alone 166

Oct 08, 2013: Angiochem to Present at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 167

Aug 19, 2013: to-BBB Receives IND Approval for Novel Brain Cancer Drug, 2B3-101 167

Jul 29, 2013: Nerviano Medical Sciences researchers report data on a novel molecule inhibitor of HSP90 168

Jun 26, 2013: Nanobiotix Announces Selection Of Its Second NanoXray Product NBTX-IV And Collaboration With National Cancer Institute For Development 168

Apr 09, 2013: biOasis Provides Update On BT2111-Herceptin Program 169

Dec 03, 2012: Geron Discontinues Development Of Brain Cancer Drug Candidate GRN1005 169

Dec 22, 2011: Geron Initiates Phase II Trial Of GRN1005 In Brain Metastases Arising From Lung Cancer 169

Nov 15, 2011: Geron Presents Final Phase I Clinical Data On GRN1005 At AACR-NCI-EORTC 170

Appendix 173

Methodology 173

Coverage 173

Secondary Research 173

Primary Research 173

Expert Panel Validation 173

Contact Us 173

Disclaimer 174

List of Tables

Number of Products under Development for Brain Metastasis, H1 2015 11

Number of Products under Development for Brain Metastasis-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Number of Products under Development by Companies, H1 2015 (Contd..1) 14

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Development by Companies, H1 2015 (Contd..1) 19

Products under Investigation by Universities/Institutes, H1 2015 20

Brain Metastasis-Pipeline by AbbVie Inc., H1 2015 21

Brain Metastasis-Pipeline by AngioChem Inc., H1 2015 22

Brain Metastasis-Pipeline by BBB Therapeutics B.V., H1 2015 23

Brain Metastasis-Pipeline by biOasis Technologies Inc., H1 2015 24

Brain Metastasis-Pipeline by Bristol-Myers Squibb Company, H1 2015 25

Brain Metastasis-Pipeline by Diffusion Pharmaceuticals LLC, H1 2015 26

Brain Metastasis-Pipeline by e-Therapeutics plc, H1 2015 27

Brain Metastasis-Pipeline by Exelixis, Inc., H1 2015 28

Brain Metastasis-Pipeline by GlaxoSmithKline plc, H1 2015 29

Brain Metastasis-Pipeline by Hutchison MediPharma Limited, H1 2015 30

Brain Metastasis-Pipeline by Komipharm International Co., Ltd., H1 2015 31

Brain Metastasis-Pipeline by Nanobiotix, H1 2015 32

Brain Metastasis-Pipeline by Nektar Therapeutics, H1 2015 33

Brain Metastasis-Pipeline by Nerviano Medical Sciences S.r.l., H1 2015 34

Brain Metastasis-Pipeline by Novartis AG, H1 2015 35

Brain Metastasis-Pipeline by Pfizer Inc., H1 2015 36

Brain Metastasis-Pipeline by Philogen S.p.A., H1 2015 37

Brain Metastasis-Pipeline by Phosplatin Therapeutics LLC, H1 2015 38

Brain Metastasis-Pipeline by Puma Biotechnology, Inc., H1 2015 39

Brain Metastasis-Pipeline by Radius Health, Inc., H1 2015 40

Brain Metastasis-Pipeline by Sanofi, H1 2015 41

Brain Metastasis-Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 42

Brain Metastasis-Pipeline by Tocagen Inc., H1 2015 43

Assessment by Monotherapy Products, H1 2015 44

Assessment by Combination Products, H1 2015 45

Number of Products by Stage and Target, H1 2015 47

Number of Products by Stage and Mechanism of Action, H1 2015 50

Number of Products by Stage and Route of Administration, H1 2015 52

Number of Products by Stage and Molecule Type, H1 2015 54

Brain Metastasis Therapeutics-Recent Pipeline Updates, H1 2015 115

Brain Metastasis-Dormant Projects, H1 2015 163

Brain Metastasis-Discontinued Products, H1 2015 164

List of Figures

Number of Products under Development for Brain Metastasis, H1 2015 11

Number of Products under Development for Brain Metastasis-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 44

Assessment by Combination Products, H1 2015 45

Number of Products by Top 10 Targets, H1 2015 46

Number of Products by Stage and Top 10 Targets, H1 2015 46

Number of Products by Top 10 Mechanism of Actions, H1 2015 49

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 49

Number of Products by Top 10 Routes of Administration, H1 2015 51

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 52

Number of Products by Top 10 Molecule Types, H1 2015 53

Number of Products by Stage and Top 10 Molecule Types, H1 2015 54

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

AbbVie Inc.

AngioChem Inc.

BBB Therapeutics B.V.

biOasis Technologies Inc.

Bristol-Myers Squibb Company

Diffusion Pharmaceuticals LLC

e-Therapeutics plc

Exelixis, Inc.

GlaxoSmithKline plc

Hutchison MediPharma Limited

Komipharm International Co., Ltd.


Nektar Therapeutics

Nerviano Medical Sciences S.r.l.

Novartis AG

Pfizer Inc.

Philogen S.p.A.

Phosplatin Therapeutics LLC

Puma Biotechnology, Inc.

Radius Health, Inc.


Spectrum Pharmaceuticals, Inc.

Tocagen Inc.

Brain Metastasis Therapeutic Products under Development, Key Players in Brain Metastasis Therapeutics, Brain Metastasis Pipeline Overview, Brain Metastasis Pipeline, Brain Metastasis Pipeline Assessment

select a license

Single User License
USD 2000 INR 136140
Site License
USD 4000 INR 272280
Corporate User License
USD 6000 INR 408420



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]